Physician profile
Javier Gomez
NPI 1861632903
$5,000.88
in general payments reported to CMS, 2019-2025
29 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $119 · 2022: $842 · 2023: $1,283 · 2024: $1,289 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,734.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,122.77 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $450.39 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $349.52 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $310.31 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $193.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $190.39 | 2019-2024 | Dificid |
| Qol Medical, LLC | $152.13 | 2022-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $103.88 | 2023-2024 | Linzess |
| Pfizer INC. | $102.54 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $101.68 | 2023-2025 | Dupixent |
| Ethicon US, LLC | $96.66 | 2019 | |
| Celgene Corporation | $85.88 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $82.69 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $77.50 | 2024 | |
| Nestle Healthcare Nutrition INC. | $71.32 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58.20 | 2024 | |
| Lilly USA, LLC | $54.87 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $49.89 | 2024-2025 | Voquezna |
| Genzyme Corporation | $49.56 | 2022 | |
| Intercept Pharmaceuticals, INC. | $48.50 | 2022-2025 | Ocaliva |
| Organon LLC | $47.54 | 2022-2023 | Hadlima |
| Boston Scientific Corporation | $45.39 | 2025 | Cre Pro, Captivator II |
| Ipsen Biopharmaceuticals, INC | $40.43 | 2024 | Bylvay, Iqirvo |
| Celltrion USA INC. | $31.14 | 2025 | Vegzelma |
| Atricure, INC. | $22.31 | 2024 | |
| Amgen INC. | $21.92 | 2023 | Amjevita, Avsola |
| E.R. Squibb & Sons, L.L.C. | $19.49 | 2022 | |
| Romark Laboratories, Lc | $11.55 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $9.43 | 2023 | Dat Closure Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.